146 related articles for article (PubMed ID: 11254449)
21. Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy.
Janbaziroudsari H; Mirzaei A; Maleki N
Bull Cancer; 2016 Sep; 103(9):730-4. PubMed ID: 27345449
[TBL] [Abstract][Full Text] [Related]
22. The presence of prostate cancer at biopsy is predicted by a number of genetic variants.
Kashyap A; Kluźniak W; Wokołorczyk D; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Świtała J; Borkowski T; Borkowski A; Antczak A; Wojnar Ł; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Piotrowski K; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Górski B; Masojć B; van de Wetering T; Menkiszak J; Akbari MR; Lubiński J; Narod SA; Cybulski C;
Int J Cancer; 2014 Mar; 134(5):1139-46. PubMed ID: 24037955
[TBL] [Abstract][Full Text] [Related]
23. ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies.
Xu B; Tong N; Li JM; Zhang ZD; Wu HF
Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):270-7. PubMed ID: 20231859
[TBL] [Abstract][Full Text] [Related]
24. Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.
Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippmann SM; Parnes HL; Dluzniewski PJ; Isaacs WB; De Marzo AM; Drake CG; Platz EA
Prostate; 2015 Sep; 75(13):1403-18. PubMed ID: 26047319
[TBL] [Abstract][Full Text] [Related]
25. Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy.
Akamatsu S; Terada N; Takata R; Kinoshita H; Shimatani K; Momozawa Y; Yamamoto M; Tada H; Kawamorita N; Narita S; Kato T; Nitta M; Kandori S; Koike Y; Inazawa J; Kimura T; Kimura H; Kojima T; Terachi T; Sugimoto M; Habuchi T; Arai Y; Yamamoto S; Matsuda T; Obara W; Kamoto T; Inoue T; Nakagawa H; Ogawa O
JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35118230
[TBL] [Abstract][Full Text] [Related]
26. Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study.
Chen YC; Giovannucci E; Kraft P; J Hunter D
Carcinogenesis; 2008 May; 29(5):999-1004. PubMed ID: 18375959
[TBL] [Abstract][Full Text] [Related]
27. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
28. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
29. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
dos Santos RM; de Jesus CM; Trindade Filho JC; Trindade JC; de Camargo JL; Rainho CA; Rogatto SR
DNA Cell Biol; 2008 Sep; 27(9):497-503. PubMed ID: 18491956
[TBL] [Abstract][Full Text] [Related]
30. Predicting the extent of prostate cancer using the combination of systematic biopsy and serum prostate-specific antigen in Japanese men.
Gohji K; Okamoto M; Takenaka A; Nomi M; Fujii A
BJU Int; 1999 Jan; 83(1):39-42. PubMed ID: 10233449
[TBL] [Abstract][Full Text] [Related]
31. TRPV6 alleles do not influence prostate cancer progression.
Kessler T; Wissenbach U; Grobholz R; Flockerzi V
BMC Cancer; 2009 Oct; 9():380. PubMed ID: 19857260
[TBL] [Abstract][Full Text] [Related]
32. Utility of incorporating genetic variants for the early detection of prostate cancer.
Nam RK; Zhang WW; Trachtenberg J; Seth A; Klotz LH; Stanimirovic A; Punnen S; Venkateswaran V; Toi A; Loblaw DA; Sugar L; Siminovitch KA; Narod SA
Clin Cancer Res; 2009 Mar; 15(5):1787-93. PubMed ID: 19223501
[TBL] [Abstract][Full Text] [Related]
33. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA;
Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471
[TBL] [Abstract][Full Text] [Related]
34. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
Akduman B; Alkibay T; Tuncel A; Bozkirli I
Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
[TBL] [Abstract][Full Text] [Related]
35. The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.
Akbari MR; Wallis CJ; Toi A; Trachtenberg J; Sun P; Narod SA; Nam RK
Br J Cancer; 2014 Sep; 111(6):1238-40. PubMed ID: 25101567
[TBL] [Abstract][Full Text] [Related]
36. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
Wiklund F; Zheng SL; Sun J; Adami HO; Lilja H; Hsu FC; Stattin P; Adolfsson J; Cramer SD; Duggan D; Carpten JD; Chang BL; Isaacs WB; Grönberg H; Xu J
Prostate; 2009 Mar; 69(4):419-27. PubMed ID: 19116992
[TBL] [Abstract][Full Text] [Related]
37. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
[TBL] [Abstract][Full Text] [Related]
38. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Freedland SJ; Mangold LA; Epstein JI; Partin AW
Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
[TBL] [Abstract][Full Text] [Related]
39. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
40. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
